ClinicalTrials.gg
RecruitingNCT06258668Updated Nov 6, 2024

Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

An observational study in Moderate-to-severe Plaque Psoriasis, sponsored by Bristol-Myers Squibb. Recruiting at 2 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-11-06.

Sponsored by Bristol-Myers Squibb · Observational

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
505
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Psoriasis by Bristol-Myers Squibb — 9 open to participants now, 14 under way, 4 of them phase 3. Psoriasis · Bristol-Myers Squibb.

Planned enrollment
8th of 14
505 · median 528
Started
2024
with 2 others
Observational
14 of 42
5 open now
Primary completion
2028-09
later than 7 of 13 live
Registered
32nd of 42
by date

Among the 42 studies in Psoriasis by Bristol-Myers Squibb, this one is the 8th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2024, is one of 14 observational ones, reaches primary completion later than 7 of the 13 other live ones, and was the 32nd registered.

Psoriasis

2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.

Browse Psoriasis studies →

Open to participants now

9 of the 42 studies in Psoriasis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.

This study: 19 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Psoriasis by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.

03

Conditions studied

  • Moderate-to-severe Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population will include adult patients in Korea who have been diagnosed with moderate-to-severe plaque psoriasis and have been prescribed treatment with deucravacitinib according to the approved product label.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants ≥19 years of age
  • Diagnosis of moderate-to-severe plaque psoriasis
  • Candidate for phototherapy or systemic therapy
  • Will begin deucravacitinib according to approved product label

Exclusion criteria

Exclusion Criteria:

  • Participants prescribed deucravacitinib for therapeutic indications not approved in Korea
  • Participants for whom deucravacitinib is as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
505 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants diagnosed with moderate-to-severe plaque psoriasis

    Drug: Deucravacitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 24 weeks from treatment initiation

  2. Number of participants with adverse drug reactions (ADRs)

    Time frame: Up to 24 weeks from treatment initiation

  3. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 24 weeks from treatment initiation

  4. Number of participants with serious adverse drug reactions (SADRs)

    Time frame: Up to 24 weeks from treatment initiation

  5. Number of participants with unexpected adverse events (AEs)

    Time frame: Up to 24 weeks from treatment initiation

  6. Number of participants with unexpected adverse drug reactions (ADRs)

    Time frame: Up to 24 weeks from treatment initiation

  7. Number of participants with unexpected serious adverse events (SAEs)

    Time frame: Up to 24 weeks from treatment initiation

  8. Number of participants with unexpected serious adverse drug reactions (SADRs)

    Time frame: Up to 24 weeks from treatment initiation

Secondary outcomes

  1. Proportion of participants with static Physician Global Assessment (sPGA) of 0 or 1

    Time frame: At Week 16 and/or Week 24 post treatment initiation

  2. Number of participants achieving Psoriasis Area and Severity Index (PASI) 75 (at least a 75% improvement in PASI score from baseline)

    Time frame: At Week 16 and/or Week 24 post treatment initiation

07

Study locations

1 of 2 sites recruiting
  • Local Institution - 0001
    Seoul, 06234, Korea, Republic of
    Withdrawn

    Not enrolling at this site.

  • Novotech Laboratory Korea Co., Ltd.
    Seoul, 06234, Korea, Republic of
    Recruiting
    • South Korea Generic Country, Site 0002 · Contact0000000000
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Sep 2028, 49 months after the start.

Of 81 industry-sponsored observational studies under Psoriasis, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 74. This study's planned 49 months is above that.

Counting every sponsor, half of 174 studies reached it within 37 months; a quarter within 23 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2024
First posted
Feb 14, 2024
StartActual
Aug 21, 2024
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Nov 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06258668
Responsible party
Sponsor
First posted
Feb 14, 2024
Start date
Aug 21, 2024
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Nov 6, 2024

Study contacts

BMS Study Connect Contact Center www.BMSStudyConnect.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion